更正：预测非转移性结直肠癌患者生存的列线图的开发与验证
Correction: Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer.
作者信息
Jiang Huihong, Tang Erjiang, Xu Dan, Chen Ying, Zhang Yong, Tang Min, Xiao Yihua, Zhang Zhiyong, Deng Xiaxing, Li Huaguang, Lin Moubin
机构信息
Department of General Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Center for Translational Medicine, Ya ngpu Hospital, Tongji University School of Medicine, Shanghai, China.
出版信息
Oncotarget. 2018 Oct 19;9(82):35373. doi: 10.18632/oncotarget.26274.
Abstract
[This corrects the article DOI: 10.18632/oncotarget.16167.].
摘要
[本文更正了文章的数字对象标识符：10.18632/oncotarget.16167。]
相似文献
1
Correction: Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer.更正：预测非转移性结直肠癌患者生存的列线图的开发与验证
Oncotarget. 2018 Oct 19;9(82):35373. doi: 10.18632/oncotarget.26274.
2
Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer.预测非转移性结直肠癌患者生存的列线图的开发与验证
Oncotarget. 2017 May 2;8(18):29857-29864. doi: 10.18632/oncotarget.16167.
3
Nomograms for predicting the prognosis of stage IV colorectal cancer after curative resection: a multicenter retrospective study.预测IV期结直肠癌根治性切除术后预后的列线图：一项多中心回顾性研究
Eur J Surg Oncol. 2015 Apr;41(4):457-65. doi: 10.1016/j.ejso.2015.01.026. Epub 2015 Feb 7.
4
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.更正：一项针对携带RAS突变的转移性结直肠癌的一线改良FOLFOXIRI联合贝伐单抗治疗的II期试验：JACCRO CC-11。
Oncotarget. 2018 Jul 6;9(52):30023. doi: 10.18632/oncotarget.25775.
5
Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.更正：肿瘤分子谱分析对预测结直肠癌治疗方案的益处。
Oncotarget. 2018 Mar 13;9(19):15165. doi: 10.18632/oncotarget.24690.
6
Correction: Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls.更正：结直肠癌患者和健康对照者粪便提取物的代谢物定量分析。
Oncotarget. 2019 Feb 26;10(17):1660. doi: 10.18632/oncotarget.26766.
7
The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.监测、流行病学和最终结果癌症生存计算器SEER*CSC：在管理式医疗环境中的验证
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):265-74. doi: 10.1093/jncimonographs/lgu021.
8
Nomograms for predicting long-term survival in patients with non-metastatic nasopharyngeal carcinoma in an endemic area.预测地方性非转移性鼻咽癌患者长期生存的列线图。
Oncotarget. 2016 May 17;7(20):29708-19. doi: 10.18632/oncotarget.8823.
9
Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.更正：STAT1与STAT3表达的比率是结直肠癌生长的一个决定因素。
Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156.
10
Correction: Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression.更正：miR-128对半乳糖凝集素-3的转录后调控促进结直肠癌进展。
Oncotarget. 2018 Feb 23;9(15):12535. doi: 10.18632/oncotarget.24558.
Zotero 插件